NI Holdings, Inc. Files Third Quarter 2017 Results
Nov 13, 2017 12:15 pm UTC| Business
FARGO, North Dakota, Nov. 13, 2017 -- NI Holdings, Inc. (NASDAQ:NODK) today reported its financial results for the quarter ended September 30, 2017. Significant items included: Net loss attributable to NI Holdings of...
Nov 13, 2017 12:05 pm UTC| Business
HALIFAX, Nova Scotia, Nov. 13, 2017 -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the Society for Immunotherapy of Cancer (SITC) has recognized...
Nov 13, 2017 12:02 pm UTC| Business
Dublin, Nov. 13, 2017 -- The "Cancer Liquid Biopsy Market Assessment" report has been added to Research and Markets' offering. The term liquid biopsy encompasses various diagnostic methods that use...
Nov 13, 2017 12:01 pm UTC| Business
PRESS RELEASE Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate ~ Data shows a 73% one-year survival rate for...
Nov 13, 2017 12:00 pm UTC| Business
Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety efficacy clinical trial (PQ-110-001: NCT03140969) in children and adults with Leber’s congenital amaurosis 10 (LCA 10).LCA 10...
Nov 13, 2017 12:00 pm UTC| Business
CARMIEL, Israel, Nov. 13, 2017 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed...
Spero Therapeutics Announces Underwriters’ Option Exercise
Nov 13, 2017 12:00 pm UTC| Business
CAMBRIDGE, Mass., Nov. 13, 2017 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug...
FDA Approval of Opdivo Injection Sparks Hope for Cancer Patients with Revolutionary Treatment Update